237 related articles for article (PubMed ID: 24455967)
1. Gain of chromosome 1q21 is an independent adverse prognostic factor in light chain amyloidosis patients treated with melphalan/dexamethasone.
Bochtler T; Hegenbart U; Kunz C; Benner A; Seckinger A; Dietrich S; Granzow M; Neben K; Goldschmidt H; Ho AD; Hose D; Jauch A; Schönland SO
Amyloid; 2014 Mar; 21(1):9-17. PubMed ID: 24455967
[TBL] [Abstract][Full Text] [Related]
2. Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens.
Bochtler T; Hegenbart U; Kunz C; Granzow M; Benner A; Seckinger A; Kimmich C; Goldschmidt H; Ho AD; Hose D; Jauch A; Schönland SO
J Clin Oncol; 2015 Apr; 33(12):1371-8. PubMed ID: 25779559
[TBL] [Abstract][Full Text] [Related]
3. Prognostic impact of cytogenetic aberrations in AL amyloidosis patients after high-dose melphalan: a long-term follow-up study.
Bochtler T; Hegenbart U; Kunz C; Benner A; Kimmich C; Seckinger A; Hose D; Goldschmidt H; Granzow M; Dreger P; Ho AD; Jauch A; Schönland SO
Blood; 2016 Jul; 128(4):594-602. PubMed ID: 27257181
[TBL] [Abstract][Full Text] [Related]
4. Additional genetic abnormalities significantly worsen poor prognosis associated with 1q21 amplification in multiple myeloma patients.
Grzasko N; Hus M; Pluta A; Jurczyszyn A; Walter-Croneck A; Morawska M; Chocholska S; Hajek R; Dmoszynska A
Hematol Oncol; 2013 Mar; 31(1):41-8. PubMed ID: 22674819
[TBL] [Abstract][Full Text] [Related]
5. Gain of 1q21 is an unfavorable genetic prognostic factor for multiple myeloma patients treated with high-dose chemotherapy.
Nemec P; Zemanova Z; Greslikova H; Michalova K; Filkova H; Tajtlova J; Kralova D; Kupska R; Smetana J; Krejci M; Pour L; Zahradova L; Sandecka V; Adam Z; Buchler T; Spicka I; Gregora E; Kuglik P; Hajek R
Biol Blood Marrow Transplant; 2010 Apr; 16(4):548-54. PubMed ID: 20005965
[TBL] [Abstract][Full Text] [Related]
6. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis.
Jaccard A; Moreau P; Leblond V; Leleu X; Benboubker L; Hermine O; Recher C; Asli B; Lioure B; Royer B; Jardin F; Bridoux F; Grosbois B; Jaubert J; Piette JC; Ronco P; Quet F; Cogne M; Fermand JP;
N Engl J Med; 2007 Sep; 357(11):1083-93. PubMed ID: 17855669
[TBL] [Abstract][Full Text] [Related]
7. Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load.
Neben K; Jauch A; Hielscher T; Hillengass J; Lehners N; Seckinger A; Granzow M; Raab MS; Ho AD; Goldschmidt H; Hose D
J Clin Oncol; 2013 Dec; 31(34):4325-32. PubMed ID: 24145347
[TBL] [Abstract][Full Text] [Related]
8. Cyclin kinase subunit 1B nuclear expression predicts an adverse outcome for patients with relapsed/refractory multiple myeloma treated with bortezomib.
Chen MH; Qi C; Reece D; Chang H
Hum Pathol; 2012 Jun; 43(6):858-64. PubMed ID: 22047644
[TBL] [Abstract][Full Text] [Related]
9. Lenalidomide and dexamethasone in relapsed/refractory immunoglobulin light chain (AL) amyloidosis: results from a large cohort of patients with long follow-up.
Basset M; Kimmich CR; Schreck N; Krzykalla J; Dittrich T; Veelken K; Goldschmidt H; Seckinger A; Hose D; Jauch A; Müller-Tidow C; Benner A; Hegenbart U; Schönland SO
Br J Haematol; 2021 Oct; 195(2):230-243. PubMed ID: 34341985
[TBL] [Abstract][Full Text] [Related]
10. Oral cyclic melphalan and dexamethasone for patients with AL amyloidosis.
Sanchorawala V; Seldin DC; Berk JL; Sloan JM; Doros G; Skinner M
Clin Lymphoma Myeloma Leuk; 2010 Dec; 10(6):469-72. PubMed ID: 21156464
[TBL] [Abstract][Full Text] [Related]
11. Novel recurrent chromosomal aberrations detected in clonal plasma cells of light chain amyloidosis patients show potential adverse prognostic effect: first results from a genome-wide copy number array analysis.
Granzow M; Hegenbart U; Hinderhofer K; Hose D; Seckinger A; Bochtler T; Hemminki K; Goldschmidt H; Schönland SO; Jauch A
Haematologica; 2017 Jul; 102(7):1281-1290. PubMed ID: 28341732
[TBL] [Abstract][Full Text] [Related]
12. Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomide.
Palladini G; Russo P; Foli A; Milani P; Lavatelli F; Obici L; Nuvolone M; Brugnatelli S; Invernizzi R; Merlini G
Ann Hematol; 2012 Jan; 91(1):89-92. PubMed ID: 21533608
[TBL] [Abstract][Full Text] [Related]
13. [Autologous peripheral blood hematopoietic cell transplantation in the treatment of AL-amyloidosis].
Smirnova AG; Smirnov AV; Zander A; Afanas'ev BV
Ter Arkh; 2010; 82(10):61-4. PubMed ID: 21341467
[TBL] [Abstract][Full Text] [Related]
14. 1p21 deletions are strongly associated with 1q21 gains and are an independent adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma.
Chang H; Qi X; Jiang A; Xu W; Young T; Reece D
Bone Marrow Transplant; 2010 Jan; 45(1):117-21. PubMed ID: 19448682
[TBL] [Abstract][Full Text] [Related]
15. Abnormal FISH in patients with immunoglobulin light chain amyloidosis is a risk factor for cardiac involvement and for death.
Warsame R; Kumar SK; Gertz MA; Lacy MQ; Buadi FK; Hayman SR; Leung N; Dingli D; Lust JA; Ketterling RP; Lin Y; Russell S; Hwa L; Kapoor P; Go RS; Zeldenrust SR; Kyle RA; Rajkumar SV; Dispenzieri A
Blood Cancer J; 2015 May; 5(5):e310. PubMed ID: 25933374
[TBL] [Abstract][Full Text] [Related]
16. High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study.
Perz JB; Schonland SO; Hundemer M; Kristen AV; Dengler TJ; Zeier M; Linke RP; Ho AD; Goldschmidt H
Br J Haematol; 2004 Dec; 127(5):543-51. PubMed ID: 15566357
[TBL] [Abstract][Full Text] [Related]
17. Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain amyloidosis: results of a phase II trial.
Cohen AD; Zhou P; Chou J; Teruya-Feldstein J; Reich L; Hassoun H; Levine B; Filippa DA; Riedel E; Kewalramani T; Stubblefield MD; Fleisher M; Nimer S; Comenzo RL
Br J Haematol; 2007 Oct; 139(2):224-33. PubMed ID: 17897298
[TBL] [Abstract][Full Text] [Related]
18. Daratumumab for systemic AL amyloidosis: prognostic factors and adverse outcome with nephrotic-range albuminuria.
Kimmich CR; Terzer T; Benner A; Dittrich T; Veelken K; Carpinteiro A; Hansen T; Goldschmidt H; Seckinger A; Hose D; Jauch A; Wörner S; Beimler J; Müller-Tidow C; Hegenbart U; Schönland SO
Blood; 2020 Apr; 135(18):1517-1530. PubMed ID: 32107537
[TBL] [Abstract][Full Text] [Related]
19. Proteasome inhibitors and IMiDs can overcome some high-risk cytogenetics in multiple myeloma but not gain 1q21.
Nahi H; Våtsveen TK; Lund J; Heeg BM; Preiss B; Alici E; Møller MB; Wader KF; Møller HE; Grøseth LA; Østergaard B; Dai HY; Holmberg E; Gahrton G; Waage A; Abildgaard N
Eur J Haematol; 2016 Jan; 96(1):46-54. PubMed ID: 25779478
[TBL] [Abstract][Full Text] [Related]
20. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes.
Palladini G; Dispenzieri A; Gertz MA; Kumar S; Wechalekar A; Hawkins PN; Schönland S; Hegenbart U; Comenzo R; Kastritis E; Dimopoulos MA; Jaccard A; Klersy C; Merlini G
J Clin Oncol; 2012 Dec; 30(36):4541-9. PubMed ID: 23091105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]